The web site logo

The American Heart Association (AHA) is the premier US scientific conference for the dissemination of results from clinical trials that can impact the management of cardiovascular risk. The research presented at the conference features insight into the potential of new approaches to lipid management and the benefits of lipid management on the progression of atherosclerosis and to overall cardiovascular health.

The National Lipid Association presents important research highlights from the 2009 AHA Scientific Sessions that impact your practice. Recorded onsite at theHeart.org studios in Orlando, FL, join Dr. Michael Davidson for a targeted discussion with a distinguished faculty panel, including: Dr. Christie Ballantyne, Director of the Center for Cardiovascular Disease Prevention at Baylor College of Medicine; Dr. Vera Bittner, Section Head of Preventive Cardiology at the University of Alabama at Birmingham and President of the National Lipid Association; and Dr. Roger Blumenthal, Director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease.

FACULTY

Chair

Michael H. Davidson, MD, FACC, FACP, FNLA
Diplomate, American Board of Clinical Lipidology
Clinical Professor
Director of Preventive Cardiology
Pritzker School of Medicine
The University of Chicago
Executive Medical Director
Radiant Research
Chicago, IL

Panelists

Christie M. Ballantyne, MD, FACC, FACP, FNLA
Diplomate, American Board of Clinical Lipidology
Professor of Medicine
Chief, Section of Atherosclerosis and Vascular Medicine
Department of Medicine
Baylor College of Medicine
Director, Center for Cardiovascular Disease Prevention
Methodist DeBakey Heart Center
Houston, TX

Vera Bittner, MD, MSPH, FACC, FNLA
Diplomate, American Board of Clinical Lipidology
Section Head of Preventive Cardiology
Division of Cardiovascular Disease
University of Alabama at Birmingham
Birmingham, AL

Roger M. Blumenthal, MD, FACC, FAHA
Diplomate, American Board of Clinical Lipidology
Professor of Medicine
Director, The Ciccarone Center for the Prevention of Heart Disease
The Johns Hopkins University School of Medicine
Baltimore, MD

LIPID INSIGHTS FROM AHA 2009

Release date: November 20, 2009
Expiration date: November 20, 2010
Format: Video Webcast

The pharmacologic armamentarium available to mitigate cardiovascular (CV) risk continues to grow, as do the options for assessing the impact of pharmacologic interventions. Dr. Michael Davidson leads a discussion on select research presented at the 2009 American Heart Association Scientific Sessions that advances our knowledge regarding the clinical utility of various therapeutic strategies to improve lipid profiles, slow the progression of atherosclerosis, and mitigate global CV risk. Joining him are Drs. Christie Ballantyne, Vera Bittner, and Roger Blumenthal.

To participate in this internet activity: (1) Review the target audience, learning objectives, and author disclosures; (2) Study the education content; (3) Take the post-test and complete the evaluation; (4) View/print certificate.

PURPOSE/GOAL
This activity will provide clinicians with education regarding recent clinical research impacting treatment rationales for the dyslipidemia patient.

TARGET AUDIENCE
This activity is intended for physicians, including lipidologists, cardiologists, endocrinologists, family/primary care practitioners, as well as other healthcare professionals interested in the prevention of CV disease.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, participants will be better able to:

• Review the scientific research highlights relating to lipid management and preventive cardiology
• Critically appraise the study design, implementation, and results from important clinical trials impacting the field of lipidology
• Determine the clinical relevance of novel research relating to dyslipidemia and how best to incorporate this into current treatment decisions

ACCREDITATION STATEMENT
The National Lipid Association is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The National Lipid Association designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

For questions or assistance, please contact Patricia Mackowiak at the NLA.

Please Note: If you have participated in this webcast presented on another website such as theHeart.org or Medscape.com and claimed credit, you may not claim credit again.

COMMERCIAL SUPPORT ACKNOWLEDGMENT
Educational grant support for this activity has been received from Merck/Schering-Plough Pharmaceuticals, Inc. and Genzyme Corporation

DISCLOSURES

Michael H. Davidson, MD

Dr. Davidson has received honoraria related to speakers bureau activities from: Merck & Co., Abbott Laboratories, Merck/Schering-Plough Pharmaceuticals, Inc., AstraZeneca, GlaxoSmithKline, Daiichi Sankyo, Inc., diaDexus, Inc., and Takeda Pharmaceuticals North America, Inc. He has received grant support related to research from: Merck & Co., AstraZeneca, Abbott Laboratories, Daiichi Sankyo, Inc., Merck/Schering-Plough Pharmaceuticals, Inc., Pfizer Inc., Roche Laboratories, Inc. and Takeda Pharmaceuticals North America, Inc. He is on the Equity/Board of Directors for Omthera, Professional Evaluation Inc., Medical Education Company and Sonogene. He is on Advisory Boards for Abbott Laboratories, AstraZeneca, Daiichi Sankyo, Inc., GlaxoSmithKline, Kinemed, Merck & Co, Merck/Schering-Plough Pharmaceuticals, Inc, Roche Laboratories, Inc. and Takeda Pharmaceuticals North America, Inc. He has done Consultant work for Abbott Laboratories, AcademicCME, AstraZeneca, Daiichi Sankyo, Inc, diaDexus, Inc, GlaxoSmithKline, Merck/Schering-Plough Pharmaceuticals, Inc., Merck & Co., Omthera, Pfizer Inc., Roche Laboratories, Inc. Pharmaceuticals, Sanofi-Aventis, Synarc, Takeda Pharmaceuticals North America, Inc., and Vindico Medical Education.

Christie M. Ballantyne, MD

Dr. Ballantyne has received honoraria related to speakers bureau activities from: Merck & Co., AstraZeneca, Merck/Schering-Plough Pharmaceuticals, Inc., Schering-Plough Corporation, GlaxoSmithKline, Reliant Pharmaceuticals, Inc., and Pfizer Inc. He has received honoraria regarding consulting from Abbott Laboratories, AstraZeneca, Atherogenics Inc., GlaxoSmithKline, Merck & Co., Merck/Schering-Plough Pharmaceuticals, Inc., Novartis Pharmaceuticals, Pfizer Inc., Sanofi-Synthelabo, Schering-Plough Corporation and Takeda Pharmaceuticals North America, Inc. He has also received research grants from Abbott Laboratories, AstraZeneca, GlaxoSmithKline, Merck & Co., Pfizer Inc., Sanofi-Synthelabo Inc., Schering-Plough Corporation, and Takeda Pharmaceuticals North America, Inc.

Vera A. Bittner, MD

Dr. Bittner has received research grants from: Merck & Co., NIH/Abbott Laboratories, NIH/Yale, National Heart, Lung and Blood Institute, Roche Laboratories, Inc., GlaxoSmithKline, and CV Therapeutics.

Roger S. Blumenthal, MD, FACC, FAHA

Dr. Blumenthal has no financial relationships or affiliations to disclose.

Staff Disclosure Statements

Caroline Fisher, Scientific Director, theheart.org - MedscapeCME has disclosed no relevant financial relationships.

National Lipid Association staff has disclosed no relevant financial relationships.

Steven J. Cally, PhD, Consulting Medical Writer, National Lipid Association has disclosed no relevant financial relationships.

HARDWARE/SOFTWARE REQUIREMENTS

lipid.org supports the following Web browsers (with javascript enabled): Internet Explorer 7 or greater, Mozilla Firefox 2 or greater, and Safari for Mac.

The activity requires that you have the Adobe Flash Player installed. This will already be the case on most systems.

Continue to View Program